Revenue $5.44B, up 7.5% on a year earlier. Cardiovascular segment net sales $3.62B, up 8.3%. Endoscopy Revenue $793.00M, up 7.6%. Diluted EPS $0.61 against $0.53.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $5.44B | $5.20B | $5.06B | +7.5% |
| Operating income | $1.18B | $1.10B | $819.00M | +43.8% |
| Net income | $905.00M | $1.34B | $795.00M | +13.8% |
| Diluted EPS | $0.61 | $0.90 | $0.53 | |
| Operating cash flow | $1.47B | $348.00M | $1.29B | +14.6% |
| Capital expenditures | -$195.00M | -$177.00M | -$157.00M | |
| Free cash flow | $1.28B | $171.00M | $1.13B | +13.3% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Cardiovascular segment net sales | $3.62B | $3.35B | +8.3% |
| Endoscopy Revenue | $793.00M | $737.00M | +7.6% |
| Neuromodulation Revenue | $341.00M | $303.00M | +12.5% |
| MedSurg segment net sales | $1.82B | $1.72B | +5.9% |
| Operational Net Sales Growth | 7% | 21.6% | |
| Organic net sales growth | 7% | 17.4% | |
| EMEA region net sales | $932.00M | $878.00M | +6.2% |
| U.S. region net sales | $3.43B | $3.22B | +6.3% |
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| Q2 FY26 | Diluted EPS | $0.82 to $0.84 | $0.61 | below |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Boston Scientific (BSX) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/BSX/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
